Entire Site
Articles/Fact Sheets
Ask the Experts
Conference Coverage
2007/2008 Conference Coverage
All Previous Conference Coverage
Upcoming Conferences
Conference Reports From Other Sources
The Body Covers: The 9th Conference on Retroviruses and Opportunistic Infections
Conference Summaries: Day Three
Wednesday, February 27, 2002
New Insights Into Mechanisms of HIV-1 Resistance to Reverse Transcriptase Inhibitors (Plenary Session 22)
Coverage by
Mark Holodniy, M.D., F.A.C.P., C.I.C.
Treatment of Patients With Drug-Resistant Virus (Plenary Session 23)
Coverage by
Mark Holodniy, M.D., F.A.C.P., C.I.C.
Antiretroviral Chemotherapy: Pathogenesis of Primary HIV Infection (Oral Abstract Session 24)
The Presence of HLA-B*5701, -DRB1*0701, and -DQ3 Is Highly Predictive of Hypersensitivity to the HIV Reverse Transcriptase Inhibitor Abacavir (Abstract 91)
Coverage by
Keith Henry, M.D.
HLA-B57 and TNF-Alpha Variants Associated With Hypersensitivity Reactions to Abacavir Among HIV-1-Positive Subjects (Abstract 92)
Coverage by
Keith Henry, M.D.
Are Episodes of Transient Viremia ("Blips" in HIV RNA) Predictive of Virologic Failure in Heavily Treatment-Experienced Patients? (Abstract 93)
Coverage by
Calvin J. Cohen, M.D., M.S.
Viral Blip Dynamics During HAART (Abstract 94)
Coverage by
Calvin J. Cohen, M.D., M.S.
Pediatric/Maternal-Fetal HIV Infection and Issues in HIV-Infected Women (Oral Abstract Session 26)
Effect of Nevirapine (NVP) for Perinatal HIV Prevention Appears Greatest Among Women With Most Advanced Disease: Subgroup Analyses of HIVNET 012 (Abstract 120)
Coverage by
Andrew T. Pavia, M.D.
Antiretroviral Chemotherapy in Drug-Naive Patients (Poster Session 60)
CHARM: A Phase III Open-Label, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of Adding Nevirapine (NVP) and/or Hydroxyurea (HU) to a Triple Nucleoside-Based Antiretroviral Drug Regimen in Treatment-Naive HIV-1-Infected Subjects (Abstract 411-W)
Coverage by
Benjamin Young, M.D., Ph.D.
Pharmacokinetics of Antiretroviral Drugs (Poster Session 62)
An Assessment of Plasma Amprenavir (APV) Pharmacokinetics (PK) Following Administration of Two GW433908 (908) and Ritonavir (RTV) Regimens in Combination With Efavirenz (EFV) in Healthy Adult Subjects (APV10010) (Abstract 431-W)
Coverage by
Keith Henry, M.D.
Previous Day's Sessions
|
Next Day's Sessions
Return to The Body's coverage of
The
9th Conference on Retroviruses and Opportunistic Infections
.